Traws Pharma, Inc.
TRAWNasdaqCIK 1130598HealthcareFiscal year ends Dec 31
Latest reported revenue, Q4 FY2025$0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept
us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Dec 31, 2025, from the 10-K filed Apr 15, 2026.Latest quarter: Q2 FY2026
Three months to Jun 30, 2026, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPS−$0.16Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.16 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure−45.5% on a year earlier - Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q3 FY20242024-09-30 | Q4 FY20242024-12-31 | Q1 FY20252025-03-31 | Q2 FY20252025-06-30 | Q3 FY20252025-09-30 | Q4 FY20252025-12-31 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $m | 0.1Revenue, Q3 FY2024, three months to 2024-09-30$57.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure | 0.1Revenue, Q4 FY2024, three months to 2024-12-31$56.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure | 0.1Revenue, Q1 FY2025, three months to 2025-03-31$57.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure | 2.7Revenue, Q2 FY2025, three months to 2025-06-30$2.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure | 0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-13, accession 0001104659-25-110845. Derived: 9-month figure less the 6-month figure.Report this figure | 0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | (14975.4%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$8.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Revenue: $57.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure | (9425.0%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$5.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Revenue: $56.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure | (9128.1%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$5.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Revenue: $57.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure | (45.7%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Revenue: $2.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | (14868.4%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$8.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Revenue: $57.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001558370-24-015752.Report this figure | (53432.1%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$29.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Revenue: $56.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure | 37701.8%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $21.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Revenue: $57.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure | (33.5%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$915.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Revenue: $2.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (1.49)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure | not reported (Diluted EPS not reported) | 2.09Diluted EPS, Q1 FY2025, three months to 2025-03-31$2.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure | (0.11)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure | (0.34)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001104659-25-110845.Report this figure | not reported (Diluted EPS not reported) | (0.53)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-061779.Report this figure | (0.16)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097261.Report this figure | |
| Free cash flow | $m | (11.5)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$11.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001104659-25-110845. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-Q filed 2025-11-13, accession 0001104659-25-110845. Derived: 9-month figure less the 6-month figure.Report this figure | (4.0)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$4.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | (2.8)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$2.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-04-15, accession 0001104659-26-043832. Derived: 12-month figure less the 9-month figure.Report this figure | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | 0.2Revenue, FY2021, twelve months to 2021-12-31$226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-30, accession 0001558370-23-005107.Report this figure | 0.2Revenue, FY2022, twelve months to 2022-12-31$226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2024-04-01, accession 0001558370-24-004525.Report this figure | 0.2Revenue, FY2023, twelve months to 2023-12-31$226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-31, accession 0001558370-25-004165.Report this figure | 0.2Revenue, FY2024, twelve months to 2024-12-31$226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure | 2.8Revenue, FY2025, twelve months to 2025-12-31$2.8m. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | (7299.1%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$16.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-30, accession 0001558370-23-005107.Revenue: $226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-30, accession 0001558370-23-005107.Report this figure | (8684.5%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$19.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-04-01, accession 0001558370-24-004525.Revenue: $226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2024-04-01, accession 0001558370-24-004525.Report this figure | (8981.4%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$20.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004165.Revenue: $226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-31, accession 0001558370-25-004165.Report this figure | (62997.3%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$142.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832.Revenue: $226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure | (640.7%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$17.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832.Revenue: $2.8m. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure | |
| Net margin | % | (7151.8%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$16.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-30, accession 0001558370-23-005107.Revenue: $226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-30, accession 0001558370-23-005107.Report this figure | (8391.2%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$19.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-04-01, accession 0001558370-24-004525.Revenue: $226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2024-04-01, accession 0001558370-24-004525.Report this figure | (8384.1%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$18.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004165.Revenue: $226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-31, accession 0001558370-25-004165.Report this figure | (73682.7%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$166.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832.Revenue: $226.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure | 328.7%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-15, accession 0001104659-26-043832.Revenue: $2.8m. XBRL concept us-gaap:Revenues. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure | |
| Diluted EPS | $ per share | (0.96)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.96 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-30, accession 0001558370-23-005107.Report this figure | (0.91)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-04-01, accession 0001558370-24-004525.Report this figure | (22.57)Diluted EPS, FY2023, twelve months to 2023-12-31−$22.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-31, accession 0001558370-25-004165.Report this figure | (35.21)Diluted EPS, FY2024, twelve months to 2024-12-31−$35.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure | 0.82Diluted EPS, FY2025, twelve months to 2025-12-31$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure | |
| Free cash flow | $m | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | (17.9)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$17.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001558370-25-004165.Capital expenditure: $14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001558370-25-004165.Report this figure | (33.4)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$29.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043832.Capital expenditure: $3.6m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure | (20.8)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$18.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-15, accession 0001104659-26-043832.Capital expenditure: $2.6m. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2026-04-15, accession 0001104659-26-043832.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2013-07-30 | Baxter Healthcare SA10% owner | Purchase | 330,000 | $15.00 | $5.0m | Form 4 |
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 2026-06-30 | $1.0m | 1,203,260 | Added+597,729 | |
| Ally Bridge Group (NY) LLC | 2026-06-30 | $663.0k | 786,236 | New+786,236 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2026-06-30 | $615.6k | 730,000 | Unchanged | |
| ADAR1 Capital Management, LLC | 2026-06-30 | $504.1k | 597,729 | Added+443,631 | |
| Lynx1 Capital Management LP | 2026-06-30 | $471.8k | 559,470 | Added+544,392 | |
| Ikarian Capital, LLC | 2026-06-30 | $403.2k | 478,142 | Reduced−200,000 | |
| SPHERA FUNDS MANAGEMENT LTD. | 2026-06-30 | $336.0k | 398,486 | New+398,486 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $278.2k | 330,049 | Added+274,856 | |
| JANE STREET GROUP, LLC | 2026-06-30 | $182.2k | 216,006 | Added+194,765 | |
| Alyeska Investment Group, L.P. | 2026-06-30 | $138.6k | 164,376 | New+164,376 |
Recent filings
All 971 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2317:18 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-26-118519 |
| 2026-10-2016:05 ET | DEF 14A | Proxy statementPeriod 2026-12-03 | 0001104659-26-117406 |
| 2026-08-1416:35 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-097261 |
| 2026-08-1416:30 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-097226 |
| 2026-07-3116:15 ET | 8-K | 3.01 Delisting notice | 0001104659-26-089220 |
| 2026-07-1016:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-082649 |
| 2026-07-0916:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-082250 |
| 2026-06-2207:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-076058 |
| 2026-06-1217:25 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-073593 |
| 2026-05-2909:00 ET | DEF 14A | Proxy statementPeriod 2026-07-08 | 0001104659-26-067945 |
Latest annual report
Form 10-K for the fiscal year ended Dec 31, 2025Filed Apr 15, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1130598
- Tickers
- TRAW
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- DE
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Former names
- Onconova Therapeutics, Inc. (to 2024-04-01); ONCONOVA THERAPEUTICS INC (to 2009-05-26)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.